CiNii Researchの本公開について

An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture

抄録

type:論文(Article)

Non-ergot-type dopamine receptor agonists such as ropinirole are used for the treatment of Parkinson disease, but they occasionally show serious side effects including sleep attacks and daytime sleepiness. These symptoms are reminiscent of narcolepsy, a major sleep disorder. Because narcolepsy is thought to result from deficiency of a hypothalamic neuropeptide orexin, we examined whether ropinirole affected the integrity of orexin-containing neurons, using organotypic slice culture of rat hypothalamus. Application of ropinirole induced a significant decrease in the number of orexin-immunoreactive neurons. The same treatment showed no significant effect on the number of melanin-concentrating hormone-immunoreactive neurons. The decrease of orexin-immunoreactive neurons was reversible after washout of ropinirole and was not accompanied by induction of cell death. Antagonism of dopamine D2 receptors and of serotonin 5-HT1A receptors attenuated the effect of ropinirole, suggesting involvement of these receptors in depletion of orexin. On the other hand, a moderate concentration of N-methyl-d-aspartate that excited orexin neurons counteracted the effect of ropinirole on the number of orexin-immunoreactive neurons. These results suggest that ropinirole can cause deficiency of orexin by inhibiting excitatory activities of orexin neurons, which may be relevant to the adverse actions of this drug on sleep and wakefulness.

source:01680102

identifier:http://www.sciencedirect.com/science/article/pii/S016801021002777X

収録刊行物

被引用文献 (0)

もっと見る

参考文献 (0)

もっと見る

関連論文

もっと見る

関連研究データ

もっと見る

関連図書・雑誌

もっと見る

関連博士論文

もっと見る

関連プロジェクト

もっと見る

関連その他成果物

もっと見る

詳細情報

ページトップへ